Flagship Ventures Fund IV, L.P.'s Net Worth

$17.4 Million

Who is Flagship Ventures Fund IV, L.P.?

Flagship Ventures Fund IV, L.P. has an estimated net worth of $17.4 Million. This is based on reported shares across multiple companies, which include Moderna, Inc., Kaleido Biosciences, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., TransMedics Group, Inc., Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., T2 Biosystems, Inc., Axcella Health Inc., and Evelo Biosciences, Inc..

SEC CIK

Flagship Ventures Fund IV, L.P.'s CIK is 0001503559

Past Insider Trading and Trends

2016 was Flagship Ventures Fund IV, L.P.'s most active year for acquiring shares with 3 total transactions. Flagship Ventures Fund IV, L.P.'s most active month to acquire stocks was the month of January. 2016 was Flagship Ventures Fund IV, L.P.'s most active year for disposing of shares, totalling 28 transactions. Flagship Ventures Fund IV, L.P.'s most active month to dispose stocks was the month of August. 2016 saw Flagship Ventures Fund IV, L.P. paying a total of $0.00 for 3,964,256 shares, this is the most they've acquired in one year. In 2016 Flagship Ventures Fund IV, L.P. cashed out on 12,513,026 shares for a total of $3,611,837.40, their largest year based on trade value.